Anika Therapeutics (NASDAQ: ANIK) — Perfil da empresa, notícias e dados financeiros
Anika Therapeutics develops advanced solutions for joint health and tissue regeneration, focusing on unmet medical needs.

Anika Therapeutics
Anika Therapeutics (NASDAQ:ANIK) focuses on developing, manufacturing, and commercializing advanced solutions for joint health, pain management, and tissue regeneration. This company's mission is to improve the lives of patients worldwide by offering innovative therapies that advance the standard of care. Anika Therapeutics' portfolio includes hyaluronic acid products for osteoarthritis pain treatment, surgical aids in the orthopedic and other healthcare markets, and therapeutic products for tissue repair and regeneration. The company is committed to scientific excellence and operates with a vision to become a leader in delivering solutions that address unmet medical needs in its targeted markets. Through its dedication to innovation, Anika Therapeutics aims to achieve sustained growth and enhance shareholder value by expanding its product offerings and reaching more patients globally.
Resumo
Operações
Produtos e/ou serviços de Anika Therapeutics
- Orthovisc and Monovisc - hyaluronic acid-based therapies for pain relief in osteoarthritis patients.
- Cingal - combines hyaluronic acid with a steroid to provide longer-lasting pain relief from osteoarthritis.
- Hyalofast - a biodegradable support for hyaluronic acid, aiding in cartilage regeneration.
- Tactoset - an injectable, bone substitute for repairing bone defects.
- Hyalobarrier - a gel used to prevent post-surgical adhesions.
- Rotium Bioresorbable Wick - designed to enhance the repair of rotator cuff injuries by improving tendon healing.
equipe executiva do Anika Therapeutics
- Cheryl Renee BlanchardExecutive Chair
- Stephen D. GriffinPresident, Principal Financial Officer, CEO & Director
- Ian W. McLeodSenior VP, Chief Accounting Officer & Treasurer
- Matthew HallExecutive Director of Corporate Development & Investor Relations
- Lisa FunicielloVP & Chief Human Resources Officer
- Ben JosephSenior Vice President of Commercial
- Mira LeiwantSenior Vice President of Regulatory, Quality & Clinical Affairs
Principais indicadores financeiros
Resultados divulgados pela Anika Therapeutics, em USD.
- Cap. de mercado
- 285,7 mi
- Receita (TTM)
- 120,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- -3.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 112,8 mi | -11,1 mi | -10,9 mi | |
| 119,9 mi | -5,1 mi | -56,4 mi | |
| 120,8 mi | 844 mil | -82,7 mi | |
| 156,2 mi | -19,4 mi | -14,9 mi |